![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: LONRF2 |
Gene summary for LONRF2 |
![]() |
Gene information | Species | Human | Gene symbol | LONRF2 | Gene ID | 164832 |
Gene name | LON peptidase N-terminal domain and ring finger 2 | |
Gene Alias | RNF192 | |
Cytomap | 2q11.2 | |
Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | Q1L5Z9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
164832 | LONRF2 | HTA12-15-2 | Human | Pancreas | PDAC | 5.50e-06 | 5.71e-01 | 0.2315 |
164832 | LONRF2 | HTA12-23-1 | Human | Pancreas | PDAC | 1.72e-06 | 8.41e-01 | 0.3405 |
164832 | LONRF2 | HTA12-25-1 | Human | Pancreas | PDAC | 3.32e-03 | 5.46e-01 | 0.313 |
164832 | LONRF2 | HTA12-26-1 | Human | Pancreas | PDAC | 4.09e-29 | 1.19e+00 | 0.3728 |
164832 | LONRF2 | HTA12-29-1 | Human | Pancreas | PDAC | 5.66e-47 | 1.04e+00 | 0.3722 |
164832 | LONRF2 | PTCwithHT_8 | Human | Thyroid | HT | 1.09e-02 | -1.33e-01 | 0.0351 |
164832 | LONRF2 | male-WTA | Human | Thyroid | PTC | 9.44e-39 | 4.65e-01 | 0.1037 |
164832 | LONRF2 | PTC01 | Human | Thyroid | PTC | 1.29e-31 | 1.15e+00 | 0.1899 |
164832 | LONRF2 | PTC03 | Human | Thyroid | PTC | 3.69e-06 | 5.88e-01 | 0.1784 |
164832 | LONRF2 | PTC04 | Human | Thyroid | PTC | 4.52e-38 | 1.10e+00 | 0.1927 |
164832 | LONRF2 | PTC05 | Human | Thyroid | PTC | 1.17e-33 | 1.83e+00 | 0.2065 |
164832 | LONRF2 | PTC06 | Human | Thyroid | PTC | 1.34e-82 | 2.56e+00 | 0.2057 |
164832 | LONRF2 | PTC07 | Human | Thyroid | PTC | 1.24e-85 | 2.02e+00 | 0.2044 |
164832 | LONRF2 | ATC12 | Human | Thyroid | ATC | 1.09e-02 | -1.39e-01 | 0.34 |
164832 | LONRF2 | ATC13 | Human | Thyroid | ATC | 6.23e-21 | 1.54e-01 | 0.34 |
164832 | LONRF2 | ATC5 | Human | Thyroid | ATC | 6.69e-15 | 1.67e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LONRF2 | SNV | Missense_Mutation | c.1190N>T | p.Ala397Val | p.A397V | Q1L5Z9 | protein_coding | tolerated(0.29) | benign(0.001) | TCGA-CV-A6K1-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
LONRF2 | SNV | Missense_Mutation | novel | c.1144N>A | p.Glu382Lys | p.E382K | Q1L5Z9 | protein_coding | tolerated(0.22) | benign(0.097) | TCGA-D6-A74Q-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
LONRF2 | SNV | Missense_Mutation | novel | c.1788N>G | p.Ile596Met | p.I596M | Q1L5Z9 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-UP-A6WW-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
LONRF2 | insertion | In_Frame_Ins | novel | c.1134_1135insACATTCTAT | p.Leu378_His379insThrPheTyr | p.L378_H379insTFY | Q1L5Z9 | protein_coding | TCGA-H7-8502-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | unknown | SD | ||
LONRF2 | SNV | Missense_Mutation | c.1236C>G | p.Asp412Glu | p.D412E | Q1L5Z9 | protein_coding | tolerated(0.3) | benign(0.028) | TCGA-EJ-7123-01 | Prostate | prostate adenocarcinoma | Male | <65 | 7 | Unknown | Unknown | SD | |
LONRF2 | SNV | Missense_Mutation | c.1190N>T | p.Ala397Val | p.A397V | Q1L5Z9 | protein_coding | tolerated(0.29) | benign(0.001) | TCGA-BR-6566-01 | Stomach | stomach adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
LONRF2 | SNV | Missense_Mutation | c.1484C>A | p.Ala495Glu | p.A495E | Q1L5Z9 | protein_coding | deleterious(0) | probably_damaging(0.969) | TCGA-CD-5800-01 | Stomach | stomach adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
LONRF2 | SNV | Missense_Mutation | c.947N>G | p.Ala316Gly | p.A316G | Q1L5Z9 | protein_coding | tolerated(0.19) | benign(0.055) | TCGA-CG-4469-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | cisplatin | SD | |
LONRF2 | SNV | Missense_Mutation | c.143C>T | p.Ser48Phe | p.S48F | Q1L5Z9 | protein_coding | tolerated(0.14) | possibly_damaging(0.503) | TCGA-IP-7968-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
LONRF2 | SNV | Missense_Mutation | novel | c.481N>G | p.Thr161Ala | p.T161A | Q1L5Z9 | protein_coding | deleterious(0.01) | possibly_damaging(0.844) | TCGA-VQ-A8P2-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unspecific | Complete Response |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |